Pricing Log in Create free account
Saturday 17 October 2026 Export EVO’s income statement to Excel — free account

Evotec AG

EVO Healthcare Drug Manufacturers Specialty & Generic

Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

1.38 0.04 −2.82%
Market cap
$504.4M
P/E
0.0×
Fwd P/E
−6.9×
Dividend yield
—
F-score
5/9
Altman Z
0.64
Beneish M
−2.62
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 5.15%

Capital & Financial Ratios $m

Market Cap 504.36
Revenue 864.62
Net Income (227.93)
Free Cash Flow (200.23)
Net Debt 11.95
Current Ratio 2.33 (at or above 1.5: strong)
Debt/Equity 0.72
P/E ratio 0.00
Fwd P/E (6.94) (negative: loss-making)
P/S ratio 0.57
P/B ratio 0.63
Past 5Y EPS Growth —
This Y EPS Growth (112.89%) (below 0%: weak)
Next Y EPS Growth 74.08% (at or above 15%: strong)
Next Y revenue growth (11.36%) (below 0%: weak)
Next 5Y EPS Growth 84.05% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 5.1×; over the ten years it ranged from 0.6× in 2026 to 15.6× in 2017.
P/S against its own 10 years 0.11%
10-year low 10-year high
P/B against its own 10 years 0.11%
10-year low 10-year high
EV/Sales against its own 10 years 0.11%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 0.02
0.02
2018 0.14
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
2017 0.14
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
2016 0.17
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 654 429 539 541
Receivables 194 171 197 155
Inventory 33 34 33 45
Other 41 54 55 60
977 738 863 847
2023 2024 2025 Q'26
Payables 145 93 73 57
ST’ Debt — — 118 72
Other 340 267 209 219
503 373 416 363

Compound Annual Growth %

10y 5y 3y
Sales 20.19% 9.28% 4.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 16.05% 2.20% (9.71%)

Revenue $m

Mar Jun Sep Dec Year
’26 183 — — — —
’25 211 194 192 295 892
’24 227 196 203 236 862
’23 — 186 214 — 846
’22 185 183 175 249 792
’21 160 167 188 216 731
’20 132 123 151 166 572
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (125) — — —
’25 (34) 28 (79) 75 (10)
’24 (52) (54) 45 81 20
’23 — (6) 23 — 39
’22 71 185 (18) (24) 214
’21 3 47 23 72 145
’20 30 (38) 32 27 51
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (17) (137) — — —
’25 (56) (1) (106) 60 (104)
’24 (94) (96) 13 56 (121)
’23 — (120) (27) — (194)
’22 23 146 (89) (57) 23
’21 (41) 3 (7) 49 4
’20 12 (51) (1) (22) (62)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.40) — — — —
’25 (0.09) (0.14) (0.14) 0.04 (0.33)
’24 (0.06) (0.29) (0.12) (0.12) (0.60)
’23 — (0.05) (0.12) — (0.26)
’22 (0.23) (0.08) (0.13) (0.07) (0.52)
’21 0.19 0.22 0.48 (0.13) 0.77
’20 0.06 (0.04) 0.00 0.00 0.02
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 1.64 3.63 7.37 10.13 10.11 17.07 7.80 7.94 2.85 2.84

Analyst estimates 2026–2028

Powerpack
High 3.89 13.21 13.13 14.88 18.58 26.57 23.63 13.49 11.67 4.80
People
People Employees 1,238 2,178 2,617 3,030 3,572 4,198 4,952 5,061 4,827 4,553
Revenue/emp, $m 0.15 0.13 0.17 0.17 0.16 0.17 0.16 0.17 0.18 0.20
Income, $m
Income, $m Revenue 182 291 443 500 572 731 792 846 862 892
Gross margin, % 35.59 32.05 29.84 29.77 25.10 24.52 23.16 22.40 14.41 14.49
EBT 36 30 85 63 29 280 (162) (87) (210) (98)
EBT margin, % 20.03 10.22 19.18 12.67 5.15 38.34 (20.49) (10.31) (24.34) (11.01)
Net income 30 27 99 42 7 255 (185) (91) (212) (117)
Depreciation 14 25 37 56 64 83 88 101 110 113
Per share, $
Per share, $ Revenue 0.69 1.00 1.50 1.67 1.86 2.20 2.24 2.39 2.43 2.51
Earnings 0.11 0.10 0.34 0.14 0.02 0.76 (0.52) (0.26) (0.60) (0.33)
Cash flow 0.28 0.04 0.63 0.16 0.17 0.43 0.61 0.11 0.06 (0.03)
Capex (0.04) (0.07) (0.11) (0.12) (0.37) (0.42) (0.54) (0.66) (0.40) (0.26)
Free cash flow 0.24 (0.02) 0.51 0.04 (0.20) 0.01 0.06 (0.55) (0.34) (0.29)
Book value 0.89 1.29 1.70 1.78 2.69 4.90 3.54 3.43 2.91 2.59
Shares, m 265 290 295 299 308 333 353 354 355 355
Valuation, ×
Valuation, × P/E 35.39 91.00 30.41 92.98 1,048.57 30.94 0.00 0.00 0.00 0.00
P/S 5.93 8.16 6.63 7.70 9.86 10.81 3.64 4.90 1.71 1.23
P/B 4.56 6.33 5.85 7.20 6.83 4.85 2.30 3.25 1.43 1.19
EV/Sales 5.33 8.54 6.53 7.98 9.85 10.23 3.34 4.28 1.90 1.19
EV/FCF 15.29 (355.12) 19.17 363.59 (89.05) 2,795.22 121.73 (11.96) (13.52) (10.25)
Cash, $m
Cash, $m Operating cash flow 75 12 185 47 51 145 214 39 20 (10)
Capex (11) (19) (33) (36) (113) (141) (191) (233) (141) (93)
Free cash flow 63 (7) 152 12 (62) 4 23 (194) (121) (104)
Balance, $m
Balance, $m Working capital 106 (74) 63 325 514 919 775 475 365 447
Total debt 32 214 133 503 545 590 518 516 425 508
Net debt (108) 111 (44) 144 (5) (426) (239) (137) (4) (31)
Shareholders’ equity 237 375 502 534 826 1,630 1,251 1,212 1,031 921
Returns, %
Returns, % ROA 8.59 4.80 11.94 3.82 0.48 11.82 (7.37) (3.77) (9.41) (5.84)
ROIC 16.84 5.45 12.48 6.46 4.22 2.52 1.36 (2.99) (9.39) (4.47)
ROE 13.71 8.96 22.68 8.23 1.05 20.77 (12.85) (7.37) (18.92) (12.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Evotec AG vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COLL Collegium Pharmaceutical, Inc. $754.6M 15.2× 12.5× +6.32% (above 0%: growing) n/m −2.14% (below 0%: shrinking) 55.18% 1.85% Compare
IRWD Ironwood Pharmaceuticals, Inc. $623.0M 4.4× 2.8× +32.62% (above 0%: growing) +106.67% (above 0%: growing) +486.70% (above 0%: growing) 100.00% 70.16% Compare
AQST Aquestive Therapeutics, Inc. $509.6M — (loss-making) — (loss-making) +38.15% (above 0%: growing) n/m −20.35% (below 0%: shrinking) 70.93% (59.51%) Compare
EVO Evotec AG $504.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%)
EOLS Evolus, Inc. $500.0M — (loss-making) — (loss-making) +21.18% (above 0%: growing) n/m +84.90% (above 0%: growing) 68.00% (5.40%) Compare
TLRY Tilray Brands, Inc. $474.4M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −36.60% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $451.7M 20.4× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32% Compare
TKNO Alpha Teknova, Inc. $408.0M — (loss-making) — (loss-making) +18.45% (above 0%: growing) n/m +74.18% (above 0%: growing) 40.09% (23.72%) Compare
EBS Emergent Biosolutions Inc. $368.1M — (loss-making) — (loss-making) +66.29% (above 0%: growing) n/m −47.68% (below 0%: shrinking) 58.56% (53.39%) Compare
Median of peers $487.2M 15.2× — +22.73% — +36.02% 56.87% (7.37%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Evotec AG (EVO) key facts

  • Strength: Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024.
  • Evotec AG (EVO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, EVO traded at $1.38, a market capitalization of $504.4 million.
  • Return on equity was −12.0% and debt-to-equity 0.72.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.64 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Evotec AG (EVO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/EVO · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com